The dichotomy of p53 regulation by noncoding RNAs

Journal of Molecular Cell Biology

Volumn 6, Issue 3, 2014, Pages 198-205

  Deng, Qipan ^a   Becker, Lindsey ^a   Ma, Xiaodong ^a   Zhong, Xiaoming ^b   Young, Ken ^c   Ramos, Kenneth ^a   Li, Yong ^a,d  

^a University of Louisville School of Medicine   (United States)

^b HENAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d SHANGHAITECH UNIVERSITY   (China)

Author keywords

3 UTR; activation; mutation; noncoding RNA; p53; polymorphism; ribosomopathies

Indexed keywords

PROTEIN P53; UNTRANSLATED RNA; 3' UNTRANSLATED REGION;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DNA DAMAGE; GENE ACTIVATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; MONOCLONAL IMMUNOGLOBULINEMIA; ONCOGENE; REGULATORY MECHANISM; REVIEW; SOMATIC MUTATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM;

3' UNTRANSLATED REGIONS; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MUTATION; NEOPLASMS; RNA, UNTRANSLATED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901713192     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mju017     Document Type: Review

References (72)

1. Amsterdam, A., Sadler, K. C., Lai, K., et al. (2004). Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2, e139.
2. - syndrome. Nat. Med. 16, 59-66.
3. Becker, L. E., Lu, Z., Chen, W., et al. (2012). Asystematic screen reveals microRNA clustersthat significantly regulatefour majorsignaling pathways. PLoSOne7, e48474.
4. Castillo, J. J., Dhami, P. K., Curry, S., et al. (2012). No association between cigarette smoking and incidenceofplasma cell myeloma:ameta- analysisof17ob-servational studies. Am. J. Hematol. 87, 729-731.
5. Chang, D. D., and Clayton, D. A. (1989). Mouse RNAase MRP RNA isencodedbya nuclear gene and contains a decamer sequence complementary to a conserved region of mitochondrial RNA substrate. Cell 56, 131-139.
6. Chi, J., Ballabio, E., Chen, X. H., et al. (2011). MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol. Direct 6, 23.
7. Chng, W. J., Price-Troska, T., Gonzalez-Paz, N., et al. (2007). Clinical significance of TP53 mutation in myeloma. Leukemia 21, 582-584.
8. Corthals, S. L., Sun, S. M., Kuiper, R., et al. (2011). MicroRNA signatures characterize multiple myeloma patients. Leukemia 25, 1784-1789.
9. Dixon, J., Jones, N. C., Sandell, L. L., et al. (2006). Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofa-cial abnormalities. Proc. Natl Acad. Sci. USA 103, 13403-13408. (Pubitemid 44380120)
10. Donehower, L. A., and Lozano, G. (2009). 20years studying p53 functionsingen-etically engineered mice. Nat. Rev. Cancer 9, 831-841.
11. Draptchinskaia, N., Gustavsson, P., Andersson, B., et al. (1999). Thegene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat. Genet. 21, 169-175. (Pubitemid 29070361)
12. Ebert, B. L., Pretz, J., Bosco, J., et al. (2008). Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339.
13. Egan, K. M., Nabors, L. B., Olson, J. J., et al. (2012). RareTP53genetic variant associated with glioma risk and outcome. J. Med. Genet. 49, 420-421.
14. Enciso-Mora, V., Hosking, F. J., DiStefano, A. L., et al. (2013). Lowpenetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br. J. Cancer 108, 2178-2185.
15. Fabbri, M., Bottoni, A., Shimizu, M., et al. (2011). Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305, 59-67.
16. Farnebo, M., Bykov, V. J., and Wiman, K. G. (2010). The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem. Biophys. Res. Commun. 396, 85-89.
17. Fernberg, P., Odenbro, A., Bellocco, R., et al. (2007). Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res. 67, 5983-5986. (Pubitemid 46985035)
18. Fletcher, O., and Houlston, R. S. (2010). Architectureof inherited susceptibility to common cancer. Nat. Rev. Cancer 10, 353-361.
19. Fonseca, R., Barlogie, B., Bataille, R., et al. (2004). Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 64, 1546-1558. (Pubitemid 38235629)
20. Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., et al. (2002). 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225-6235.
21. Gill, T., Cai, T., Aulds, J., et al. (2004). RNase MRP cleaves the CLB2 mRNA to promote cell cycle progression: novel method of mRNA degradation. Mol. Cell. Biol. 24, 945-953. (Pubitemid 38112160)
22. Gonzalez, K. D., Noltner, K. A., Buzin, C. H., et al. (2009). Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J. Clin. Oncol. 27, 1250-1256.
23. Guan, X., Wang, L. E., Liu, Z., et al. (2013). Association betweena rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. J. Cell. Mol. Med. 17, 873-878.
24. Hindorff, L. A., Gillanders, E. M., and Manolio, T. A. (2011). Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis 32, 945-954.
25. Hu, W., Chan, C. S., Wu, R., et al. (2010). Negativeregulationoftumor suppressor p53 by microRNA miR-504. Mol. Cell 38, 689-699.
26. Jones, N. C., Lynn, M. L., Gaudenz, K., et al. (2008). Prevention of the neurocristo-pathyTreacherCollins syndrome through inhibitionofp53function. Nat. Med. 14, 125-133. (Pubitemid 351214559)
27. Kumar, M., Lu, Z., Takwi, A. A., et al. (2011). Negativeregulationofthe tumor suppressor p53 gene by microRNAs. Oncogene 30, 843-853.
28. Kyle, R. A., Therneau, T. M., Rajkumar, S. V., et al. (2006). Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362-1369.
29. Lalloo, F., Varley, J., Ellis, D., et al. (2003). Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361, 1101-1102. (Pubitemid 36369565)
30. Le, M. T., Teh, C., Shyh-Chang, N., et al. (2009). MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23, 862-876.
31. ′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121, 4529-4540.
32. Lionetti, M., Biasiolo, M., Agnelli, L., et al. (2009). Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114, e20-e26.
33. Liu, J. M., and Ellis, S. R. (2006). Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood 107, 4583-4588. (Pubitemid 43882601)
34. Lohr, J. G., Stojanov, P., Lawrence, M. S., et al. (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879-3884.
35. Lu, Q., Wierzbicki, S., Krasilnikov, A. S., et al. (2010). Comparison of mitochon-drialandnucleolarRNaseMRPrevealsidenticalRNAcomponentswithdistinct enzymatic activities and protein components. RNA 16, 529-537.
36. Lygerou, Z., Allmang, C., Tollervey, D., et al. (1996). Accurate processing of aeu-karyotic precursor ribosomal RNA by ribonuclease MRP in vitro. Science 272, 268-270. (Pubitemid 26119139)
37. MacInnes, A. W., Amsterdam, A., Whittaker, C. A., et al. (2008). Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc. Natl Acad. Sci. USA 105, 10408-10413.
38. Maida, Y., Yasukawa, M., Furuuchi, M., et al. (2009). An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461, 230-235.
39. Maida, Y., Kyo, S., Lassmann, T., et al. (2013). Off-target effect of endogenous siRNA derived from RMRP in human cells. Int. J. Mol. Sci. 14, 9305-9318.
40. Maier, B., Gluba, W., Bernier, B., et al. (2004). Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306-319. (Pubitemid 38199255)
41. Martin, A. N., and Li, Y. (2007). RNase MRPRNA and human genetic diseases. Cell Res. 17, 219-226. (Pubitemid 46438719)
42. McFarland C. D., Korolev, K. S., Kryukov, G. V., et al. (2013). Impact of deleterious passenger mutations on cancer progression. Proc. Natl Acad. Sci. USA 110, 2910-2915.
43. McKusick, V. A., Eldridge, R., Hostetler, J. A., et al. (1965). Dwarfism in the Amish. Ii. cartilage-hair hypoplasia. Bull. Johns Hopkins Hosp. 116, 285-326.
44. Mills, P. K., Newell, G. R., Beeson, W. L., et al. (1990). History of cigarette smoking and risk of leukemia and myeloma: results from the adventist health study. J. Natl Cancer Inst. 82, 1832-1836.
45. Morin, R. D., Mendez-Lago, M., Mungall, A. J., et al. (2011). Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303.
46. Mukherjee, S., Firpo, E. J., Wang, Y., et al. (2011). Separationof telomerase functions by reverse genetics. Proc. Natl Acad. Sci. USA 108, E1363-E1371.
47. Muller, P. A., and Vousden, K. H. (2013). p53 mutations in cancer. Nat. Cell Biol. 15, 2-8.
48. Narla, A., and Ebert, B. L. (2010). Ribosomopathies: human disorders of ribo-some dysfunction. Blood 115, 3196-3205.
49. Neveu, P., Kye, M. J., Qi, S., et al. (2010). MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 7, 671-681.
50. Olive, K. P., Tuveson, D. A., Ruhe, Z. C., et al. (2004). Mutant p53gainoffunction in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860. (Pubitemid 40017690)
51. Oren, M., and Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107.
52. Palmero, E. I., Achatz, M. I., Ashton-Prolla, P., et al. (2010). Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 22, 64-69.
53. Pasqualucci, L., Trifonov, V., Fabbri, G., et al. (2011). Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837.
54. Pichiorri, F., Suh, S. S., Ladetto, M., et al. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 105, 12885-12890.
55. Psaltopoulou, T., Sergentanis, T. N., Kanellias, N., et al. (2013). Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies. Int. J. Cancer 132, 2413-2431.
56. Ridanpaa, M., van Eenennaam, H., Pelin, K., et al. (2001). Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104, 195-203. (Pubitemid 32174836)
57. Rosenbluh, J., Nijhawan, D., Chen, Z., et al. (2011). RMRP is a non-coding RNA essential for early murine development. PLoS One 6, e26270.
58. Schmitt, M. E., and Clayton, D. A. (1992). Yeast site-specific ribonucleoprotein endoribonuclease MRP contains an RNA component homologous to mammalian RNase MRP RNA and essential for cell viability. Genes Dev. 6, 1975-1985.
59. Stacey, S. N., Sulem, P., Jonasdottir, A., et al. (2011). A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43, 1098-1103.
60. Swarbrick, A., Woods, S. L., Shaw, A., et al. (2010). miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 16, 1134-1140.
61. ′ untranslated region. Biochem. Biophy. Res. Commun. 396, 435-439.
62. Tyner, S. D., Venkatachalam, S., Choi, J., et al. (2002). p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53. (Pubitemid 34062443)
63. Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing thep53network. Nature 408, 307-310.
64. Volinia, S., Calin, G. A., Liu, C. G., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261. (Pubitemid 43271657)
65. Vousden, K. H., and Prives, C. (2009). Blinded by the light: the growing complexity of p53. Cell 137, 413-431.
66. Whibley, C., Pharoah, P. D., and Hollstein, M. (2009). p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95-107.
67. ′ end formation. Science 226, 1045-1051. (Pubitemid 15217822)
68. Williams, R. R., and Horm, J. W. (1977). Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J. Natl Cancer Inst. 58, 525-547. (Pubitemid 8056552)
69. Xu-Monette, Z. Y., Wu, L., Visco, C., et al. (2012). Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood 120, 3986-3996.
70. Yu, X., Vazquez, A., Levine, A. J., et al. (2012). Allele-specific p53 mutant reactivation. Cancer Cell 21, 614-625.
71. Zhang, Y., and Lu, H. (2009). Signalingto p53: ribosomal proteins find their way. Cancer Cell 16, 369-377.
72. Zhou, L., Yuan, Q., and Yang, M. (2012). Afunctional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma. Gene 506, 295-297.